The natural variant of the cytochrome P450 enzyme CYP2D6.1, CYP2D6.17, is most common in African populations, has three amino acid substitutions (T107I, R296C, and S486T) compared to the wild-type, and is known to have a different ligand preference from CYP2D6.1. It is becoming increasingly important to understand differences in the metabolism of medicines in different ethnic groups in order to assess the relevance of clinical data from different countries. This study investigated differences in the inhibition profiles of drugs for CYP2D6 with respect to gene polymorphisms. Firstly, we used computer docking with six drugs to several CYP2D6.1 structures, sampled from the trajectory of MD simulations, and calculated MM-GB/SA scores representing binding free energies. We then used regression analysis to predict the potency with which drugs inhibited CYP2D6.1 based on MM-GB/SA scores. The pKi-values obtained were in good agreement with experimental values measured for the six drugs (r 2 = 0.81). We carried out the same analysis for CYP2D6.17 and the pKi-values calculated were also in good agreement with experimental values (r 2 = 0.92). Finally, we were able to successfully explain the different abilities of CYP2D6.1 and CYP2D6.17 to metabolize drugs in different ethnic groups with reference to their 3D-structures.
Introduction
It is becoming increasingly important for pharmaceutical companies to understand how gene polymorphism can affect the function of personalized medicines. Gene polymorphism will also become a consideration during drug development in the near future. This study focused on CYP2D6 gene polymorphisms.
The CYP enzymes are responsible for about 90% of drug metabolism, with different isoforms accounting for the following % of the total CYP contribution: CYP1A2 (4%), CYP2A6 (2%), CYP2C9 (10%), CYP2C19 (2%), CYP2E1 (2%), CYP2D6 (30%), and CYP3A4 (50%). 1) Although hepatic CYP2D6 constitutes only 1-2% of total CYP protein in the liver, it contributes significantly to the metabolism of most drugs.
2) CYP2D6 appears to have a high affinity and low capacity for its substrates, becoming saturated at relatively low concentrations, and so is subject to inhibition by a number of drugs, resulting in clinically significant drug-drug interactions (DDIs).
3) To estimate DDIs, it is important to know the potencies of all relevant metabolic enzymes. Otherwise, drugs might appear to be ineffective in clinical trials, because of an excessively low plasma concentration, or severely toxic, if the plasma concentration was excessive.
Phenotypically, CYP2D6 polymorphisms have been categorized as ultrarapid metabolizers (UM), extensive metabolizers (EM), intermediate metabolizers (IM), and poor metabolizers (PM). Although the potency of null enzymes (e.g. PM) can be taken as zero, for enzymes with reduced function (e.g. IM), we have to estimate the potency of enzymes with respect to the metabolism/ inhibition of drugs correctly to understand DDIs.
The polymorphisms seen in IM individuals are well known to differ greatly in different races. There are two main natural variants, CYP2D6.10 and CYP2D6.17. CYP2D6.10 has two amino acid substitutions, P34S and S486T, and is common in Asian populations.
3) The frequency of CYP2D6.10 in different Asian countries is Japan, 38.6% 4) ; Korea, 53.8% 5) ; Taiwan, 65.6% 6) ; and the China mainland, 51.6%. 7) It is known to be unstable at high temperature 8) ; therefore, a simple comparison with wild-type CYP2D6.1 cannot be made. CYP2D6.17 is normally expressed and common in African populations, and has three amino acid substitutions, T107I, R296C, and S486T. 3, 9) The frequency of CYP2D6.17 in different African countries is Zimbabwe, 34% 10) ; Ethiopia 9% 11) ; Tanzania, 18% 12) ; Gabon, 24% 13) ; and Ghana, 28%. 14) CYP2D6.17 and CYP2D6.1 are well known to have different ligand preferences, with the metabolic potency of CYP2D6.17 being lower than that of CYP2D6.1 in most cases. [15] [16] [17] [18] These days, the clinical data obtained may be submitted to regulatory authorities in countries other than that where the clinical trials were carried out. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E5 guidelines 19) have been published as a guide to data extrapolation and suggest a threestep process.
Step one is the assessment of the completeness of the clinical data package for a drug. If complete, step two is to assess the product's sensitivity to ethnic factors, and the third step is to judge the requirement for bridging studies to assess the effects that ethnic factors could have on the medicine's safety, efficacy, and dose-response. [19] [20] [21] [22] [23] [24] [25] [26] Consequently, having methods for estimating the effects of ethnic factors on drug metabolism is very important for judging the acceptability of foreign clinical data.
We have investigated drug sensitivity in different ethnic groups by calculating differences in inhibition profiles for CYP2D6.1 and CYP2D6.17. Inhibition constants (Ki) for the CYP2D6 inhibitors (S)-fluoxetine, (S)-norfluoxetine, imipramine, cocaine, quinidine, and thioridazine for both CYP2D6.1 and CYP2D6.17 have been reported previously, using the supersome expression system. 27) All compounds tested were more potent inhibitors of CYP2D6.1 than CYP2D6.17. However, the inhibitors could be classified into two groups based on differences in their inhibition profiles. For (S)-fluoxetine and (S)-norfluoxetine there was little difference in their inhibition profiles for CYP2D6.1 and CYP2D6.17. In contrast, imipramine, cocaine, quinidine, and thioridazine showed large differences in their inhibition profiles for CYP2D6.1 and CYP2D6.17. In a previous study of CYP3A4, it was suggested that differences in the inhibition profiles between the natural variant enzymes was due to differences in the ligand binding poses. 28) Another study reported that the substitutions T107I and R296C in CYP2D6 played important roles in these differences in inhibition, but the S486T substitution might not, in light of the result of in vitro metabolic experiments and site-directed mutagenesis experiments. 29) Several other amino acids have been considered to have important roles in ligand recognition by CYP2D6. Phe120 and Phe483 have been suggested to mediate hydrophobic interactions, such as ³-³ interactions, and Glu216, Asp301, and Ser304 to mediate hydrogen bonding with ligands, from the results of docking studies and site-directed mutagenesis experiments. [30] [31] [32] [33] [34] [35] [36] [37] [38] However, these earlier docking experiments used an apoprotein CYP2D6.1 structure [PDB (Protein Data Bank) code 2F9Q]. 39) Recently, the X-ray structure for CYP2D6.1 co-crystallized with prinomastat (PDB code 3QM4) has been resolved, which clearly showed that a large conformational change in CYP2D6 resulted from ligand binding and which identified the novel F' helix. 40) This study aimed to estimate differences in the metabolic sensitivity of ethnic groups to drugs and investigate how this related to 3D-structural differences between CYP2D6.1 and CYP2D6.17. We decided to use an X-ray structure for CYP2D6.1 co-crystallized with prinomastat (PDB code 3QM4) as the docking protein. To obtain active conformations for CYP2D6.1 and CYP2D6.17 in aqueous solution, we sampled several structures from the trajectory of molecular dynamics (MD) simulations, as this would allow us to take protein flexibility into consideration in our docking studies. We performed computer docking with six drugs to several of these CYP2D6.1 structures and calculated Molecular Mechanics-based scoring methods coupled with Generalized Born surface area (MM-GB/SA) scores representing binding free energies. We then used regression analysis based on MM-GB/SA scores to predict the potency of the drugs' inhibition of CYP2D6.1. We also analyzed the inhibition profiles of the drugs for CYP2D6.17, as for CYP2D6.1.
Materials and Methods
CYP2D6.1 structure preparation: We used the X-ray crystallographic structure PDB code 3QM4 (prinomastat-CYP2D6 complex) and removed all crystallographic water molecules. This structure included residues 34 to 497, with deletions at the terminal regions. We used the Schrödinger Suite 2010 of programs (Schrödinger Inc., New York, NY) throughout this study, unless otherwise stated. We used the Prime program to compensate for amino acids missing between residues 34 and 497. Finally, this structure was minimized using force field OPLS-2005.
Computational docking in CYP2D6.1: We used the Glide SP docking program, using the following parameters: a protein van der Waals (vdW) radius scaling of 1.0, a ligand vdW radius scaling of 0.80, and a grid size (centered on the amino acid residues within 4 Å of the ligand in the co-crystallized X-ray structure) of 10 © 10 © 10 Å 3 . CYP2D6.17 structure preparation: We used the mutate process in the Maestro fragment tool program to introduce the three substitutions (T107I, R296C, and S486T) in CYP2D6.17 into the CYP2D6.1 (PDB code 3QM4) structure. Using the 34 to 497 residues, as for CYP2D6.1, we modeled CYP2D6.17 using the Prime program. Finally, this structure was minimized using the force field OPLS-2005.
Computational docking in CYP2D6.17: We used the Glide SP docking program and the following parameters: a protein vdW radius scaling of 1.0, a ligand vdW radius scaling of 0.75, and a grid size (centered on the amino acid residues within 4 Å of the ligand in the co-crystallized X-ray structure) of 10 © 10 © 10 Å 3 .
Molecular dynamics:
We sampled active conformations in aqueous solution using MD simulations with prepared prinomastat-CYP2D6.1 and prinomastat-CYP2D6.17 complexes. The calculations presented here used the force field OPLS-2005 with explicit solvent and were run using the default parameters in the Desmond program. We added a 10 Å layer of surrounding water molecules using the TIP3P water model. The systems were neutralized with Na + ions. Periodic boundary conditions (PBC) and a 9.0 Å cut-off for non-bond interactions were used, with electrostatic interactions treated using the Particle Mesh Ewald (PME) method with a 10 ¹8 tolerance. A Desmond default relaxation protocol was employed prior to MD simulations. After relaxation, a 5 ns simulation in an NPT ensemble (T = 310.5K, thermostat relaxation time = 1.0 ps, P = 1 atm, and barostat relaxation time = 2.0 ps) was performed for each system using a Nosé-Hoover thermostat and MartynaTobias-Klein barostat. Trajectory atomic coordinate data were recorded every 20 ps. From the MD trajectory obtained for the ligand binding space residues (within 4 Å of prinomastat), the conformations of structures between 4 and 5 ns were clustered using the distance matrix of the Maestro clustering program. We determined cluster size by visual inspection of the distance matrix and selected a representative structure from each cluster as closest to the average root-mean-square (RMS) value in the cluster area. Finally, the representative structures were minimized using the Desmond program; prinomastat, water, and Na + were removed; and these structures were then used for computational docking.
Ligand dataset: Figure 1 shows the ligand structures used and Table 1 shows their inhibitory activities. These compounds, which have diverse structures, were selected from the literature, as were their inhibitory activities for CYP2D6.1 and CYP2D6.17.
27)
Ligand preparation: The ligands' 2D structures were converted into 3D structures using the LigPrep program. The final step was an energy minimization of the 3D conformers using OPLS-2005. Ionization states were determined using ADMET Predictor (Simulations Plus Inc., Lancaster, CA). We used the ConfGen program for conformational searches.
Pose determination by MM-GB/SA score: Figure 2 shows the overall procedure for pose determination. To identify the actual pose of each ligand from the results of docking studies, we obtained a MM-GB/SA score, which measures the binding free energy in ligand-protein complex at single point using the MM-GB/SA method in the Prime program. For each ligand, the docking poses with the top 30% Glide scores were rescored using the Prime/MM-GBSA approach.
41) The docked poses were minimized around 101 amino acids from the inhibitors using the local optimization feature in Prime and the energies of the complexes were calculated using the OPLS-2005 force field and GB/SA continuum solvent model. The binding free energy ("G bind ) was then estimated using the equation:
where E MM was the difference in energy between the ligand-protein complex and the sum of the energies of the ligand and free protein, using the OPLS-2005 force field; "G solv was the difference in the GB/SA solvation energy between the ligand-protein complex and the sum of the solvation energies for the ligand and free protein; and "G SA was the difference in the surface area energy between the ligand-protein complex and the sum of the surface area energies for the ligand and free protein. Corrections for entropic changes were not applied. The dielectric constants were set to 1.0. The lowest energy pose was selected as the determined pose.
Validation of pose determination: To validate the pose accuracy, we compared the pose of prinomastat (co-crystal of PDB code 3QM4) determined by our procedure (see Fig. 2 ) and its position determined by X-ray crystallography in CYP2D6.1 (PDB code 3QM4). 40) As there is no X-ray structure for a CYP2D6.17 complex, we compared the poses determined for the reference compound, debrisoquine, with CYP2D6.1 and CYP2D6.17. We used debrisoquine as its metabolic kinetic parameters are very similar to CYP2D6.1 and CYP2D6.17 and its metabolic sites are known to be identical to each other. 27) Thus, obtaining identical poses for debrisoquine in CYP2D6.1 and CYP2D6.17 would suggest that the accuracy of determining poses in CYP2D6.17 would be comparable with that in CYP2D6.1.
Regression analysis for predicting a drug's inhibitory activity for CYP2D6.1 and CYP2D6.17 using MM-GB/SA scores: To predict the inhibitory activities of drugs for CYP2D6.1 and CYP2D6.17, we constructed regression equations for inhibitory activity versus MM-GB/SA score for each ligand's determined pose (Microsoft μ Excel μ for Mac 2011).
Fig. 1. Chemical structures of the CYP2D6 inhibitors used
The circles identify significant groups within the ligands, used in Figure 4 and Supplementary Figure 2 , which are: a1, amine, a2, trifluoromethylphenyl, and a3, phenyl groups in (S)-fluoxetine; b1, azabicycloctane and b2, phenyl groups in cocaine; sa1, amine, sa2, trifluoromethylphenyl, and sa3, phenyl groups in (S)-norfluoxetine; sb1, amine and sb2, dibenzoazepine groups in imipramine; sc1, hydroxyl, sc2, azabicyclo, and sc3, quinoline groups in quinidine; and sd1, piperidine and sd2, sulfanylphenothioazine groups in thioridazine. 
Results
Validation of the determined pose in CYP2D6.1: When we compared the pose position of prinomastat with CYP2D6.1 determined by our in silico procedure (Fig. 2) and its position in the co-crystallized protein-ligand complex (PDB code 3QM4) determined by X-ray crystallography, the positions of prinomastat were very similar (RMSD of heavy atom: 1.23 Å) and the interactions between ligand and amino acid residues were comparable ( Supplementary Figs. 1a and 1b) .
Calculation of inhibitory activity for CYP2D6.1: We found that the trajectory of heavy atomic RMSD from the initial structure in the MD simulation of CYP2D6.1 reached equilibrium with respect to structural fluctuations between 4 and 5 ns (Supplementary Fig. 2a) . The MD trajectory of the ligand binding space residue conformations for structures in this time interval were clustered and the distance matrix obtained is shown in Supplementary Figure 3a . By visual inspection, we clustered these snapshots into 2 groups. The elapsed times of the MD simulations for the representative structures selected from each cluster were 4.24 and 4.84 ns.
Using our validated procedure for pose determination (Fig. 2) , six inhibitors were docked into these representative CYP2D6.1 structures and MM-GB/SA scores were calculated (Table 2a) . To investigate the validity of using MM-GB/SA scores to evaluate the drugs' inhibitory activities for CYP2D6.1, we plotted the MM-GB/SA scores for poses versus experimental pKi values (Fig. 3a) . We then constructed regression equations for the inhibitory activity and the MM-GB/SA score for each ligand's determined pose. The regression equation obtained for CYP2D6.1 (Table 2a) Validation of the determined pose in CYP2D6.17: When we compared the poses of debrisoquine in CYP2D6.1 and CYP2D6.17 using our pose determination procedure (Fig. 2) , we found they were very similar (RMSD of heavy atom: 1.88 Å). The interactions between the ligand and amino acids were comparable and the known metabolic site of debrisoquine was sufficiently close to the heme group in both CYP2D6.1 (6.57 Å) and CYP2D6.17 (7.07 Å) to be metabolically active ( Supplementary Figs. 1c and 1d) .
Calculation of inhibitory activity for CYP2D6.17: Based on the drugs' inhibitory activities for CYP2D6.1, we calculated the six drugs' inhibitory activities for CYP2D6.17. The equilibrated MD trajectory of the ligand binding space residue conformations In Silico Study of CYP2D6. 1 and CYP2D6.17 in CYP2D6.17 between 4 and 5 ns were clustered into 3 groups (Supplementary Fig. 2b and Supplementary Fig. 3b ). The elapsed times for the MD simulations of the structures selected from each cluster were 4.50, 4.72, and 4.88 ns. The six drugs were docked into these representative CYP2D6.17 structures and MM-GB/SA scores were calculated (Table 2b) . To validate the use of MM-GB/SA scores for evaluating the drugs' inhibitory activities for CYP2D6.17, we plotted the MM-GB/SA scores of poses versus experimental pKi values (Fig. 3b) and constructed regression equations, as above. The regression equation obtained for CYP2D6.17 (Table 2b) Fluoxetine: The orientation of fluoxetine's docking pose was similar in both CYP2D6.1 and CYP2D6.17 (Fig. 4a) . Hydrogen bonds were observed between the fluoxetine amine group (Fig. 4, a1 ) and Asp301 and Ser304 in both molecules, with a further hydrogen bond between the trifluoromethylphenyl group (Fig. 4, a2) and Gln244 in CYP2D6.1. Hydrophobic interactions were observed between two phenyl groups in fluoxetine and both CYP2D6.1 and CYP2D6.17, with one phenyl group adjacent to the roof of the ligand binding space (Fig. 4, a2) and the other adjacent to the heme (Fig. 4. a3 ) in both CYP2D6.1 and CYP2D6. 17 .
Cocaine: The orientation of cocaine's docking pose in CYP2D6.1 was very different from that in CYP2D6.17 (Fig. 4b) . In CYP2D6.1, there was a hydrogen bond between the azabicycloctane group (Fig. 4, b1) and Ser304 and there were hydrophobic interactions involving the azabicycloctane group, adjacent to the roof of the ligand binding space (Fig. 4, b1) , and a phenyl group, adjacent to the heme (Fig. 4, b2) . In CYP2D6.17, no hydrogen bond was observed, but hydrophobic interactions were seen with the azabicycloctane (Fig. 4, b1) and phenyl groups (Fig. 4, b2) . However, the phenyl group (Fig. 4, b2) was not as close to the heme in CYP2D6.17 as in CYP2D6.1. There were also fewer hydrophobic interaction between the phenyl group (Fig. 4, b2) and amino acids in CYP2D6.17 than in CYP2D6.1.
Discussion
Inhibitory activity calculations based on MM-GB/SA score: Based on the validation of our pose determination procedure using prinomastat and debrisoquine, we considered that the poses determined for the ligands used in this study were much the same as the active conformations in both CYP2D6.1 and CYP2D6.17 ( Supplementary Fig. 1 ). The six ligands used in this docking study were assumed to be suitable for comparing CYP2D6.1 and CYP2D6.17 inhibition profiles, since the Ki data used were obtained in the same experimental study using a supersome expression system ( Table 1) .
27)
The high correlation coefficient between MM-GB/SA scores for these ligands' determined poses and the experimental pKi values suggested that MM-GB/SA scores reflected experimental pKi values well (Figs. 3a and 3b) . However, the absolute values of MM-GB/SA scores for CYP2D6.1 and CYP2D6.17 were inconsistent with experimental values, with a tendency for absolute values in CYP2D6.17 to be higher than in CYP2D6.1 ( Table 2) . Two possible reasons for this are firstly, that, despite the rapidity of the Prime/MM-GB/SA calculation, some improvements are still needed to achieve a high accuracy, 42) and secondly, that this inconsistency in the absolute values of MM-GB/SA scores could be traced to the difficulty in calculating binding free energies of the different proteins, CYP2D6.1 and CYP2D6.17, arising from the T107I, R296C, and S486T substitutions. These inconsistencies could therefore not be addressed at present. We constructed regression equations for the drugs' inhibitory activity for CYP2D6.1 and CYP2D6.17 individually, and both gave results with high r 2 values ( Table 2) . We concluded that the regression analyses performed in this study could contribute to the estimation of the metabolic sensitivity of ethnic groups to developing drug candidates by obtaining only MM-GB/SA scores.
Relationship between pose and inhibitory activity: Analyzing the poses determined for the ligands used in this study suggested that the degree of the differences seen in the inhibition profiles for CYP2D6.1 and CYP2D6.17 depended largely on the pose determined for each ligand. 28) For fluoxetine and norfluoxetine, whose inhibitory activities for CYP2D6.1 and CYP2D6.17 were very similar ( Table 1) , we thought that this similarity derived from the similarity of the determined poses in the two molecules ( Fig. 4a and Supplementary Fig. 4a) .
For cocaine, which had very different inhibitory activities for CYP2D6.1 and CYP2D6.17 (Table 1) , there were also differences in the overall orientations of their poses in CYP2D6.1 and CYP2D6.17. The positions of a phenyl group in CYP2D6.1 and CYP2D6.17 were very different (Fig. 4b) . In CYP2D6.1 there was a hydrogen bond and many hydrophobic interactions with hydrophobic amino acids, such as Val370 and Val374, which did not occur with Val370 and Val374 in CYP2D6.17. Therefore, we concluded that cocaine's higher inhibitory activity in CYP2D6.1, compared to CYP2D6.17, was partly due to hydrophobic interactions with hydrophobic residues such as Val370 and Val374. As for cocaine, imipramine, quinidine, and thioridazine showed different inhibition profiles for CYP2D6.1 and CYP2D6.17 and also different overall orientations in the poses determined in CYP2D6.1 and CYP2D6.17 ( Supplementary Figs. 4b-4d) . Moreover, the specific hydrophobic interactions with Val370 and Val374 in CYP2D6.1, but not in CYP2D6.17, were also observed for imipramine ( Supplementary Fig. 4b) .
From all the poses determined for the compounds used in this study, we concluded that Gln244, Asp301, and Ser304 play important roles in hydrogen bonding and Phe120 and Phe483 play important roles in hydrophobic interactions (Fig. 4 and Supplementary Fig. 4) , which is consistent with previous studies. [30] [31] [32] [33] [34] [35] [36] [37] Analyses of representative protein structures sampled from the trajectory of MD simulations: Investigating representative structures from the trajectory of the MD simulation allowed us to identify differences in the protein structures of CYP2D6.1 and CYP2D6.17 and helped elucidate differences in their drug interactions. There were major structural differences between CYP2D6.1 and CYP2D6.17. The protein surface of their ligand binding spaces, as shown in Figure 5 , showed that the amino acids around the heme group could envelop the ligand binding space in the representative CYP2D6.1 structures, but in the CYP2D6.17 structures there were clefts on the surface of the ligand binding space.
We examined the positions of the three amino acid substitutions in CYP2D6.17. Firstly we considered the T107I substitution that lay in the ¡B'-helix. In CYP2D6.1, hydrogen bonds formed between Thr107 and Leu110/Gly111/Phe112 within the B'-C loop and also between Thr107 and Val104 within the ¡B'-helix (Figs. 6a and 6b) . On the other hand, in CYP2D6.17, hydrogen bonds formed between Ile107 and Gly111/Phe112 (Figs. 6c-6e) . Secondly we considered the R296C substitution that lay in the ¡I-helix. In CYP2D6.1, a hydrogen bond formed between Arg296 and Asp252 within the ¡G-helix (Figs. 6a and 6b) , whereas in CYP2D6.17, Cys296 formed no hydrogen bond (Figs. 6c-6e) . Thirdly we considered the S486T substitution within the ¢4-2 sheet. In both CYP2D6.1 and CYP2D6.17, hydrogen bonds formed between either Ser486 or Thr486 and Val480, which lay in the ¢4-1 sheet (Figs. 6a-6e) . In summary, all three amino acids (Thr107, Arg296, and Ser486) in CYP2D6.1, which were replaced in CYP2D6.17, formed hydrogen bonds (Figs. 6a and 6b) . In CYP2D6.17, Cys296 formed no hydrogen bonds, Ile107 formed fewer hydrogen bonds than Thr107 in CYP2D6.1 (Figs. 6c-6e ), but at the S486T site, hydrogen bonds with Val480 were formed in both CYP2D6.1 and CYP2D6.17. This suggested that T107I and R296C, but not S486T, were important in differences in the protein conformation between CYP2D6.1 and CYP2D6.17. This is consistent with the results of previous in vitro metabolic experiments and site-directed mutagenesis experiments. 29) We also found that the amino acids forming the cleft in the representative CYP2D6.17 structures were in the B'-C and K-¢1-4 loops and the ¡F'-helix, and the conformations of these secondary structures were different in the representative CYP2D6.1 and CYP2D6.17 structures (Supplementary Table 1a and Fig. 6f ). When we examined the conformational difference of each residue forming the cleft in CYP2D6.17, we found that the conformations of Phe219 and Val374 were different in CYP2D6.1 and CYP2D6.17 ( Supplementary Table 1b and Fig. 6g) . Moreover, the amino acids that formed this cleft were almost all hydrophobic residues (i.e. Val119, Phe120, Leu121, Phe219, Leu220, Arg221, Val370, Pro371, Leu372, Gly373, and Val374). When docked with cocaine, Val370 and Val374 were implicated as important in ligand interaction with CYP2D6.1, but not with CYP2D6.17 (Fig. 4b) . Therefore, these residues were suggested to contribute to hydrophobic interaction between ligand and CYP2D6.1, but they could not contribute to the ligand-protein interaction in CYP2D6.17, as they were sufficiently far from the ligand to form the cleft. We considered these results to well reflect the higher inhibitory activity of each compound for CYP2D6.1 compared to CYP2D6.17. 27) In conclusion, we have demonstrated a method that could be used to estimate the metabolic sensitivity of different ethnic groups to drugs, using the 3D structural differences between CYP2D6 variants. We calculated the inhibition potencies of six drugs for CYP2D6.1 and CYP2D6.17 by regression analysis based on MM-GB/SA scores, using receptor structures sampled from MD simulation and computer ligand docking. The calculated values were in good agreement with the experimental values for both CYP2D6.1 (r 2 = 0.81) and CYP2D6.17 (r 2 = 0.92). We believe that using regression analyses in this way could contribute to the estimation of the metabolic sensitivity that might be expected in different ethnic groups to drug candidates at relatively early stages in drug development.
